At what point does upper abdominal pain warrant urgent assessment?

I have kept a symptom diary against dose dates, which turns out to have been the useful thing.

I would like to set this up properly once, rather than adjust it repeatedly.

My budget is real but not tight, and my tolerance for uncertainty is low.

What would you do, and what would make you change course?

The relevant detail is that the distinction worth making early is between a tolerability problem, which is unpleasant and self-limiting, and a clinical problem, which is neither. They present differently and the thresholds for each are worth writing down before you need them.

The gallbladder signal tracks the rate of weight loss more than it tracks the drug. Rapid mobilisation of adipose tissue increases biliary cholesterol saturation and reduces gallbladder motility; that combination is lithogenic whether the loss came from a drug, a very-low-energy diet or bariatric surgery. The drug contribution on top of that is present but smaller than the rate contribution.

Gastrointestinal adverse events, indicative pooled rates

Ranges span agents and doses; read the specific prescribing information for a specific figure.

Put another way, injection-site reactions are more often diluent-related than peptide-related. Benzyl alcohol sensitivity is uncommon but real, and it presents as a consistent local reaction at every site with a preserved diluent and no reaction with an unpreserved one — which is a straightforward thing to establish. Injection depth is the other common cause: intradermal placement stings and welts, subcutaneous placement usually does not.

I would flag that attributing a symptom to a drug is a hypothesis, and the base rate of these symptoms in the general population is high enough that the hypothesis is often wrong.

A symptom diary with dates against dose steps answers most of these questions without anyone needing to guess.

Put another way, the mechanism explains the pattern. Delayed gastric emptying plus central appetite suppression produces early satiety, and early satiety plus a slowed transit produces exactly the symptom cluster people report.

Early satiety is not a side effect; it is the mechanism being observable. The useful distinction is between satiety, where you stop eating without distress, and aversion, where the thought of food is unpleasant. The first is the intended effect. The second frequently precedes the dose being too high or escalated too fast.

The telogen effluvium timing signature is the diagnostic feature: hair enters the shedding phase two to four months after the insult, so shedding that starts at month three of rapid loss and peaks around month four to five is the expected pattern. Shedding that starts in week two is not telogen effluvium and warrants a different question. In either case the follicle is not destroyed and regrowth is the rule.

The caveat that actually matters: this is pattern recognition from published data, not a clinical assessment of you. Anything severe, persistent or accompanied by systemic features belongs with a clinician the same day.

Fix the fixable causes first — fluid, electrolytes, sleep, intake — before concluding that the compound is responsible.

Look at the placebo arm before concluding anything about attribution. The placebo-arm rates for most of these events are not small, because the events themselves are common in the underlying population.

Constipation outlasts the nausea because it has two causes and only one of them resolves. Gastric emptying accommodates over weeks; total intake, and therefore stool volume and the osmotic load reaching the colon, does not recover until intake does. This is why fibre alone can make it worse — you add bulk to a system that is short of water and short of motility.

Concretely, fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.

SURMOUNT-1 reported gastrointestinal events as the most frequent adverse events, mostly mild to moderate and mostly during escalation, with discontinuation for adverse events in the single digits per cent[1].

One qualification — reported incidence in a monitored trial population is a lower bound on what happens in an unmonitored one, because trial participants were escalated to protocol and supported through it.

If the timing does not fit the escalation, look for another explanation before settling on the drug.

edited 10 Dec 2024 by u100_marks — fixed an arithmetic slip in the third paragraph

The honest framing is that this is very common, usually self-limiting, and occasionally the presentation of something that is not self-limiting at all — and the differentiating features are specific enough to be worth knowing.

Vomiting matters mostly through its consequences. Loss of gastric fluid depletes sodium, chloride and potassium, and hypokalaemia presents as exactly the fatigue and cramping people attribute to the drug. Persistent vomiting also makes a renal panel uninterpretable, because a pre-renal picture looks like renal impairment.

Telogen effluvium following substantial weight loss is documented independently of any pharmacotherapy, which is the cleanest argument that the rate of loss rather than the agent is the primary driver.

Write down in advance which symptoms mean stop and seek care. It is a short list and it is much easier to write when you are well.

edited 10 Dec 2024 by zainab_mustafa — added the placebo-arm figures

Stated carefully, timing is the most useful diagnostic feature here and it is the one most often omitted from the question.

Pancreatitis red flags worth memorising rather than looking up: severe, persistent epigastric pain radiating to the back, worse lying flat and better sitting forward, with nausea and vomiting that does not settle. That combination is an urgent assessment, not a dose adjustment. An isolated lipase elevation without that picture is common and usually not pancreatitis.

Most of this resolves. The point of knowing the pattern is to recognise the small fraction that does not.

edited 28 Aug 2024 by kwn_analytical — updated for the 2026 guidance change